期刊文献+

中医药干预癌症免疫逃逸的研究进展 被引量:7

Research progress of traditional Chinese medicine intervention in cancer immune escape
在线阅读 下载PDF
导出
摘要 免疫逃逸是指恶性肿瘤细胞通过免疫编辑过程后具备浸润、转移等恶性生物学行为,并逃脱免疫系统的监视和清除,最终促进恶性肿瘤病情发生发展的过程。除其他因素外,免疫细胞还积极影响肿瘤发展的每一步,决定了癌细胞在受威胁的微环境中生存的机会。一旦发现第一个癌细胞,抗肿瘤免疫机制就会被激活,并在原发肿瘤形成和转移过程中发挥作用。然而,免疫功能受损时,肿瘤细胞就会通过逃避或者阻挠免疫反应的机制来促进自身的增殖,就会导致肿瘤的持续性发展。而中医药干预癌症免疫逃逸机制需以“扶正”为基本原则,补益正气以治其本,增强免疫细胞对癌细胞的杀伤力,阻止癌症免疫逃逸,从而抑制癌症的发展。根据现有文献分析可知,目前通过免疫逃逸治疗癌症多用补益类药物,这可能是因为机体免疫调节功能与中医“扶正”观点相符合。因此,研究癌症免疫逃逸机制不仅能够提高治疗癌症的效率,而且通过对中医药的开发利用,能够延缓疾病的发展进程,更好的改善患者的生存质量。 Immune escape refers to the process in which malignant tumor cells have malignant biological behaviors such as infiltration and metastasis after immune editing,and escape the surveillance and clearance of the immune system,which ultimately promotes the occurrence and development of malignant tumor.Among other factors,immune cells actively influence every step of tumor development,determining cancer cells′chances of survival in a threatened microenvironment.Once the first cancer cell is found,anti-tumor immune mechanisms are activated and play a role in primary tumor formation and metastasis.However,when immune function is impaired,tumor cells will promote their own proliferation by evading or obstructing the mechanism of immune response,which will lead to the sustainable development of tumors.The mechanism of traditional Chinese medicine intervention in cancer immune escape should be based on the basic principle of"Fuzheng",supplementing the healthy qi to cure its root,enhancing the lethality of immune cells to cancer cells,preventing cancer immune escape,and thus inhibiting the development of cancer.According to the analysis of existing literature,at present,cancer is treated with many supplements through immune escape,which may be because the immune regulation function of the body is consistent with the view of"Fuzheng"in traditional Chinese medicine.Therefore,the study of cancer immune escape mechanism can not only improve the efficiency of cancer treatment,but also delay the development of the disease and better improve the quality of life of patients through the development and utilization of traditional Chinese medicine.
作者 纪柯伊 李根林 吴宿慧 李寒冰 JI Ke-yi;LI Gen-lin;WU Su-hui;LI Han-bing(Henan University of Traditional Chinese Medicine;Henan Engineering Research Center of Healthy Aging Industry,Zhengzhou 450046,China)
出处 《天然产物研究与开发》 CAS CSCD 北大核心 2024年第1期167-174,136,共9页 Natural Product Research and Development
基金 河南省科技攻关计划(232102311191) 河南省高校科技创新团队支持计划(24IRTSTHN040) 河南中医药大学2022年度研究生科研创新类项目(2022KYCX004)。
关键词 免疫逃逸 癌症 中医药 immune escape cancer Chinese medicine
  • 相关文献

参考文献22

二级参考文献145

  • 1邱显本,尚海辉,曾凡杨,胡婷婷,李晶.紫草素下调miR-224表达对鼻咽癌细胞生物学行为的影响[J].热带医学杂志,2022,22(5):634-638. 被引量:2
  • 2陈清勇,方睿,杨凌,江中勇,詹建伟,王彦刈.化疗对肺癌患者外周血Th1/Th2的影响及茶多酚的调控研究[J].临床内科杂志,2007,24(5):307-309. 被引量:7
  • 30' HARA A J, BELLL D W. The genomics and genetics of endometrial cancer[J], Adv Genomics Genet, 2012, 2012(2):33-47.
  • 4MATIAS-GUIU X, PRAT J. Molecular pathology of endometrial carcinoma[J]. Histopathology, 2013, 62(1):111-123.
  • 5SLOMOVITZ B M, COLEMAN R L. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer[J]. Clinl Cancer Res, 2012, 18(21):5856-5864.
  • 6GARCIA-DIOS D A, LAMBRECHTS D, COENEGRACHTS L, et al. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carclnoma[J]. Gyneco Oncol, 2013, 128(2):327-334.
  • 7JIN S, MUTVEI A P, CHIVUKULA I V, et al. Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKKα/IKKβ. Oncogene, 2012 [Epub ahead of print].
  • 8YU H, JOVE R. The STATs of cancer-new molecular targets come of age [J]. Nat Rev Cancer, 2004, 4(2):97-105.
  • 9DEBNATH B, XU 5, NEAMATI N. Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein[J]. J Med Chemy, 2012, 55(1 5):6645-6668.
  • 10CHEN C L, HSIEH F C, LlEBLEIN J C, et al. Stat3 activation in human endometrial and cervical cancers[J]. Br J Cancer, 2007, 96(4):591-599.

共引文献205

同被引文献151

引证文献7

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部